NZ594004A - Production of closed linear dna - Google Patents
Production of closed linear dnaInfo
- Publication number
- NZ594004A NZ594004A NZ594004A NZ59400410A NZ594004A NZ 594004 A NZ594004 A NZ 594004A NZ 594004 A NZ594004 A NZ 594004A NZ 59400410 A NZ59400410 A NZ 59400410A NZ 594004 A NZ594004 A NZ 594004A
- Authority
- NZ
- New Zealand
- Prior art keywords
- production
- dna
- closed linear
- linear dna
- under conditions
- Prior art date
Links
- 102000053602 DNA Human genes 0.000 abstract 5
- 108020004414 DNA Proteins 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 230000001737 promoting effect Effects 0.000 abstract 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 abstract 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 abstract 1
- 230000003321 amplification Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6846—Common amplification features
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
- C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0901593.4A GB0901593D0 (en) | 2009-01-30 | 2009-01-30 | Production of closed linear DNA |
| PCT/GB2010/000165 WO2010086626A1 (en) | 2009-01-30 | 2010-02-01 | Production of closed linear dna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ594004A true NZ594004A (en) | 2013-01-25 |
Family
ID=40469378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ594004A NZ594004A (en) | 2009-01-30 | 2010-02-01 | Production of closed linear dna |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9109250B2 (enExample) |
| EP (3) | EP3150722B1 (enExample) |
| JP (2) | JP2012516147A (enExample) |
| KR (1) | KR101926662B1 (enExample) |
| CN (2) | CN102301010B (enExample) |
| AU (1) | AU2010209532B2 (enExample) |
| BR (1) | BRPI1005683B1 (enExample) |
| CA (1) | CA2751130C (enExample) |
| DK (2) | DK3150722T3 (enExample) |
| EA (1) | EA021069B1 (enExample) |
| ES (2) | ES2400890T3 (enExample) |
| GB (1) | GB0901593D0 (enExample) |
| IL (1) | IL213930A (enExample) |
| LT (1) | LT3150722T (enExample) |
| MX (1) | MX2011007937A (enExample) |
| NZ (1) | NZ594004A (enExample) |
| SG (1) | SG173102A1 (enExample) |
| WO (1) | WO2010086626A1 (enExample) |
| ZA (1) | ZA201105013B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017060650A1 (fr) | 2015-10-08 | 2017-04-13 | Jean-Marc Limacher | Composition anti-tumorale |
| WO2025190971A1 (fr) | 2024-03-13 | 2025-09-18 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2351294B8 (es) * | 2009-07-02 | 2012-06-06 | Consejo Superior De Investigaciones Científicas (Csic) | Metodo para la replicación, amplificación, o secuenciación de un adn molde. |
| GB201013153D0 (en) * | 2010-08-04 | 2010-09-22 | Touchlight Genetics Ltd | Primer for production of closed linear DNA |
| US9290800B2 (en) | 2013-03-15 | 2016-03-22 | Pacific Biosciences Of California, Inc. | Targeted rolling circle amplification |
| GB201502645D0 (en) * | 2015-02-17 | 2015-04-01 | Touchlight Genetics Ltd | Method |
| KR20180107109A (ko) | 2015-12-22 | 2018-10-01 | 큐어백 아게 | Rna 분자 조성물의 제조 방법 |
| RU2616279C1 (ru) * | 2015-12-28 | 2017-04-13 | Федеральное государственное бюджетное учреждение науки Институт биохимии и генетики Уфимского научного центра Российской академии наук (ИБГ УНЦ РАН) | Способ получения маркерных лестниц для гель-электрофоретического определения размеров фрагментов нуклеиновых кислот |
| US10077459B2 (en) | 2016-05-04 | 2018-09-18 | General Electric Company | Cell-free protein expression using rolling circle amplification product |
| CN109844134B (zh) * | 2016-08-16 | 2023-05-05 | 塔驰莱特Ip有限公司 | 闭合线性dna的生产 |
| TW201936201A (zh) * | 2017-12-14 | 2019-09-16 | 美商堅固生物科技公司 | 基因之非病毒生產及遞送 |
| GB201721846D0 (en) * | 2017-12-22 | 2018-02-07 | Arecor Ltd | Novel composition |
| CN109971825B (zh) * | 2017-12-28 | 2020-11-10 | 南京金斯瑞生物科技有限公司 | 快速制备桑格测序模板的方法 |
| GB201805683D0 (en) * | 2018-04-05 | 2018-05-23 | Touchlight Ip Ltd | Reprogramming vectors |
| AU2019290228A1 (en) * | 2018-06-22 | 2021-01-28 | AskBio Inc. | Vectors for gene delivery that persist within cells |
| CN113195001B (zh) * | 2018-11-02 | 2025-04-29 | 耐克基因有限责任公司 | 重组细小病毒载体及其制备方法和用途 |
| GB201905651D0 (en) * | 2019-04-24 | 2019-06-05 | Lightbio Ltd | Nucleic acid constructs and methods for their manufacture |
| US20220233685A1 (en) | 2019-06-18 | 2022-07-28 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
| JP2022536945A (ja) | 2019-06-18 | 2022-08-22 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ |
| MA56520A (fr) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Construction de l'interleukine 12 recombinante et ses utilisations |
| CA3143679A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
| JP2022536850A (ja) | 2019-06-18 | 2022-08-19 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ |
| WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
| WO2020254876A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Virus-like particle delivery of hepatitis b virus (hbv) vaccines |
| US20220305118A1 (en) | 2019-06-20 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines |
| WO2020255062A1 (en) | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines |
| EP3792367A1 (en) | 2019-09-11 | 2021-03-17 | Universität Bielefeld | Method for the production of raav and method for the in vitro generation of genetically engineered, linear, single-stranded nucleic acid fragments containing itr sequences flanking a gene of interest |
| MX2022003291A (es) | 2019-09-18 | 2022-09-09 | Intergalactic Therapeutics Inc | Vectores de adn sinteticos y metodos de uso. |
| GB201915163D0 (en) | 2019-10-18 | 2019-12-04 | Univ Southampton | Cancer vaccine |
| WO2021123062A1 (en) | 2019-12-20 | 2021-06-24 | Keygene N.V. | Ngs library preparation using covalently closed nucleic acid molecule ends |
| AU2021207683A1 (en) * | 2020-01-17 | 2022-08-11 | Asklepios Biopharmaceutical, Inc. | Recombinant AAV production |
| CA3164387A1 (en) * | 2020-01-31 | 2021-08-05 | Julen Oyarzabal Santamarina | Process for the production of closed linear dna |
| KR20230057487A (ko) | 2020-03-04 | 2023-04-28 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 게놈 조정을 위한 방법 및 조성물 |
| GB202007428D0 (en) | 2020-05-19 | 2020-07-01 | Fabricnano Ltd | Polynucleotide synthesis |
| AU2021289600A1 (en) | 2020-06-12 | 2023-01-19 | University Of Rochester | Encoding and expression of ACE-tRNAs |
| EP4203999A1 (en) | 2020-08-26 | 2023-07-05 | Scancell Limited | Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen |
| JP2023543602A (ja) | 2020-10-06 | 2023-10-17 | キージーン ナムローゼ フェンノートシャップ | 標的化された配列付加 |
| EP4317424A4 (en) | 2021-03-29 | 2025-10-22 | Kaneka Corp | VECTOR, METHOD FOR PREPARING COVALENTLY BONDED CLOSED LINEAR DNA USING SAME, METHOD FOR PREPARING PARVOVIRAL VECTOR, AND PARVOVIRAL VECTOR PRODUCTION CELL |
| GB202108176D0 (en) | 2021-06-08 | 2021-07-21 | Touchlight Ip Ltd | Vector |
| IL308705A (en) | 2021-06-08 | 2024-01-01 | Touchlight Ip Ltd | LENTIVIRAL vector |
| WO2022272297A1 (en) | 2021-06-25 | 2022-12-29 | Oxford Biomedica Solutions Llc | Adeno-associated virus packaging systems |
| EP4370151A1 (en) | 2021-07-13 | 2024-05-22 | Stonehaven Incubate AG | Composition and uses thereof |
| EP4124660A1 (en) | 2021-07-30 | 2023-02-01 | 4basebio, S.L.U. | Linear dna with enhanced resistance against exonucleases and methods for the production thereof |
| AU2022343268A1 (en) | 2021-09-08 | 2024-03-28 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| GB202114105D0 (en) | 2021-10-01 | 2021-11-17 | Fabricnano Ltd | Nucleotide synthesis |
| WO2023069948A1 (en) | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| WO2023114901A2 (en) | 2021-12-15 | 2023-06-22 | Oxford Biomedica Solutions Llc | Methods and compositions for the production of adeno-associated virus |
| EP4453204A4 (en) * | 2021-12-23 | 2025-12-24 | Generation Bio Co | EVOLUTIONARY, CELLULAR, HIGH-PURITY SYNTHESIS OF CLOSED-ENDED DNA VECTORS |
| CN114561372B (zh) * | 2022-04-27 | 2022-07-26 | 南京巨匠生物科技有限公司 | Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌 |
| EP4293101A1 (en) | 2022-06-14 | 2023-12-20 | Asklepios Biopharmaceutical, Inc. | Reactor with temperature control and method of using the same |
| EP4570912A1 (en) | 2022-08-10 | 2025-06-18 | Zhenjiang Probio Biotech Co., Ltd. | Method for preparing linear closed dna and plasmid for use in the method |
| WO2024039652A1 (en) | 2022-08-16 | 2024-02-22 | Aldevron, L.L.C. | Cell-free method of producing synthetic circular nucleic acid |
| JPWO2024058155A1 (enExample) | 2022-09-12 | 2024-03-21 | ||
| AU2023352042A1 (en) | 2022-09-29 | 2025-04-10 | Ceva Hampton Limited | Vaccine construct and uses thereof |
| EP4365303A1 (en) | 2022-11-02 | 2024-05-08 | 4basebio, S.L.U. | Purification of linear dna products |
| WO2024094793A1 (en) | 2022-11-02 | 2024-05-10 | 4Basebio, S.L.U. | Purification of linear dna products |
| KR102753513B1 (ko) * | 2022-11-18 | 2025-01-13 | 최낙식 | Direct RNA 추출 버퍼 및 이의 용도 |
| WO2024121354A1 (en) | 2022-12-08 | 2024-06-13 | Keygene N.V. | Duplex sequencing with covalently closed dna ends |
| EP4638776A1 (en) | 2022-12-19 | 2025-10-29 | Thermo Fisher Scientific GENEART GmbH | Retrieval of sequence-verified nucleic acid molecules |
| EP4410995A1 (en) | 2023-02-01 | 2024-08-07 | 4basebio, S.L.U. | Linear dna with enhanced resistance against exonucleases and methods for the production thereof |
| EP4410992B1 (en) | 2023-02-01 | 2025-12-17 | 4basebio UK Ltd | Linear dna with enhanced resistance against exonucleases and methods for the production thereof |
| WO2024197081A1 (en) | 2023-03-20 | 2024-09-26 | Hc Bioscience, Inc. | Minimally-sized dna threads for trna therapy |
| CN116606834A (zh) * | 2023-04-10 | 2023-08-18 | 天津中合基因科技有限公司 | 多种具有切割连接活性的原端酶及其应用 |
| AU2024258816A1 (en) | 2023-04-18 | 2025-10-23 | Uniqure Biopharma B.V. | Generation of adeno-associated virus capsid libraries for insect cells |
| WO2024256842A1 (en) | 2023-06-16 | 2024-12-19 | Touchlight IP Limited | Therapeutic transfection |
| US11981936B1 (en) | 2023-09-29 | 2024-05-14 | New England Biolabs, Inc. | TelA variants, compositions, and methods |
| EP4553156A1 (en) | 2023-11-08 | 2025-05-14 | 4basebio UK Ltd | Synthetic dna production using cas nuclease |
| GB202319998D0 (en) | 2023-12-22 | 2024-02-07 | Touchlight Ip Ltd | duplexing method |
| EP4596713A1 (en) | 2024-02-05 | 2025-08-06 | 4basebio UK Ltd | Dna with enhanced resistance against exonucleases and methods for the production thereof |
| WO2025194042A1 (en) | 2024-03-14 | 2025-09-18 | Affinia Therapeutics Inc. | Plasmid system for production of recombinant adenoassociated virus |
| WO2025202929A1 (en) * | 2024-03-29 | 2025-10-02 | Pfizer Inc. | Methods for producing nucleic acids |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| JPH06500014A (ja) | 1990-07-25 | 1994-01-06 | シンジーン，インコーポレイテッド | 多数の核酸相補体を生成させる環状伸長法 |
| FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| US6953676B1 (en) | 1992-05-01 | 2005-10-11 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
| WO1994003624A1 (en) | 1992-08-04 | 1994-02-17 | Auerbach Jeffrey I | Methods for the isothermal amplification of nucleic acid molecules |
| US5714320A (en) | 1993-04-15 | 1998-02-03 | University Of Rochester | Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides |
| EP0636413B1 (en) | 1993-07-28 | 2001-11-14 | PE Corporation (NY) | Nucleic acid amplification reaction apparatus and method |
| FR2732971B1 (fr) | 1995-04-13 | 1997-07-04 | Genset Sa | Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| DE69612013T2 (de) | 1995-11-21 | 2001-08-02 | Yale University, New Haven | Unimolekulare segmentamplifikation und bestimmung |
| DE19648625A1 (de) | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer |
| JPH10234399A (ja) | 1997-02-28 | 1998-09-08 | Shinkinrui Kinou Kaihatsu Kenkyusho:Kk | ピシウム属菌検出用の核酸配列 |
| US6124120A (en) | 1997-10-08 | 2000-09-26 | Yale University | Multiple displacement amplification |
| US6054274A (en) * | 1997-11-12 | 2000-04-25 | Hewlett-Packard Company | Method of amplifying the signal of target nucleic acid sequence analyte |
| CA2312102C (en) | 1997-12-24 | 2007-09-04 | Cepheid | Integrated fluid manipulation cartridge |
| WO1999035281A1 (en) | 1998-01-09 | 1999-07-15 | University Of Utah Research Foundation | Method for in vitro amplification of circular dna |
| DE19826758C1 (de) | 1998-06-15 | 1999-10-21 | Soft Gene Gmbh | Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte |
| JP2002525049A (ja) | 1998-09-15 | 2002-08-13 | イェール ユニバーシティ | ローリングサークル増幅を用いる分子クローニング |
| EP1203078B1 (de) * | 1999-07-08 | 2005-05-04 | Mologen Forschungs-, Entwicklungs- und Vertriebs GmbH | Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze |
| US20040241651A1 (en) | 2000-04-07 | 2004-12-02 | Alexander Olek | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
| GB0018120D0 (en) | 2000-07-24 | 2000-09-13 | Fermentas Ab | Nuclease |
| US6977148B2 (en) | 2001-10-15 | 2005-12-20 | Qiagen Gmbh | Multiple displacement amplification |
| US20030077611A1 (en) | 2001-10-24 | 2003-04-24 | Sention | Methods and systems for dynamic gene expression profiling |
| CA2412187A1 (en) | 2001-12-21 | 2003-06-21 | University Of Western Ontario | Assay for identifying modulators of borrelia telomere resolvase |
| US7081339B2 (en) | 2002-04-12 | 2006-07-25 | Primera Biosystems, Inc. | Methods for variation detection |
| AU2003251905A1 (en) | 2002-07-12 | 2004-02-02 | Affymetrix, Inc. | Synthetic tag genes |
| US20040022764A1 (en) | 2002-07-31 | 2004-02-05 | Hanan Polansky | Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease |
| ES2270120T3 (es) * | 2002-09-23 | 2007-04-01 | Mologen Ag | Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina. |
| US7955795B2 (en) | 2003-06-06 | 2011-06-07 | Qiagen Gmbh | Method of whole genome amplification with reduced artifact production |
| US7452699B2 (en) | 2003-01-15 | 2008-11-18 | Dana-Farber Cancer Institute, Inc. | Amplification of DNA in a hairpin structure, and applications |
| ATE432365T1 (de) | 2003-02-21 | 2009-06-15 | Geneform Technologies Ltd | Verfahren, kits und reagenzien zur nukleinsäuresequenzierung |
| WO2005054435A2 (en) | 2003-11-26 | 2005-06-16 | Eppendorf Ag | Methods and compositions for in vitro amplification of extrachromosomal nucleic acid |
| BRPI0515777A (pt) * | 2004-12-11 | 2008-08-05 | Cytogenix Inc | biossìntese isenta de células de ácido nucléico de alta qualidade e usos dos mesmos |
| EP1871897B1 (en) | 2005-04-12 | 2010-09-29 | Olink AB | Methods for production of oligonucleotides |
| DE602006015633D1 (de) | 2005-04-29 | 2010-09-02 | Synthetic Genomics Inc | Amplifikation und klonierung einzelner dna-moleküle mittels rolling-circle-amplifikation |
| US8093030B2 (en) | 2005-10-06 | 2012-01-10 | Lucigen Corporation | Thermostable viral polymerases and methods of use |
| US9029134B2 (en) | 2006-01-12 | 2015-05-12 | Lucigen Corporation | Linear vectors, host cells and cloning methods |
| CA2713101C (en) | 2006-10-06 | 2016-09-13 | Vandalia Research, Inc. | Method for a continuous rapid thermal cycle system |
| US9598724B2 (en) * | 2007-06-01 | 2017-03-21 | Ibis Biosciences, Inc. | Methods and compositions for multiple displacement amplification of nucleic acids |
| US8921072B2 (en) | 2008-09-02 | 2014-12-30 | General Electric Compnay | Methods to generate DNA mini-circles |
| GB201013153D0 (en) * | 2010-08-04 | 2010-09-22 | Touchlight Genetics Ltd | Primer for production of closed linear DNA |
| US9114399B2 (en) | 2010-08-31 | 2015-08-25 | Canon U.S. Life Sciences, Inc. | System and method for serial processing of multiple nucleic acid assays |
| EP2692870A1 (en) | 2012-08-03 | 2014-02-05 | Alacris Theranostics GmbH | Method for nucleic acid amplification |
| KR102014989B1 (ko) | 2013-04-15 | 2019-08-27 | 삼성전자주식회사 | 폴리뉴클레오티드 및 그의 용도 |
-
2009
- 2009-01-30 GB GBGB0901593.4A patent/GB0901593D0/en not_active Ceased
-
2010
- 2010-02-01 US US13/146,350 patent/US9109250B2/en active Active
- 2010-02-01 EA EA201101141A patent/EA021069B1/ru not_active IP Right Cessation
- 2010-02-01 EP EP16195596.8A patent/EP3150722B1/en not_active Revoked
- 2010-02-01 NZ NZ594004A patent/NZ594004A/xx unknown
- 2010-02-01 DK DK16195596.8T patent/DK3150722T3/da active
- 2010-02-01 LT LT16195596T patent/LT3150722T/lt unknown
- 2010-02-01 KR KR1020117018730A patent/KR101926662B1/ko active Active
- 2010-02-01 JP JP2011546955A patent/JP2012516147A/ja active Pending
- 2010-02-01 AU AU2010209532A patent/AU2010209532B2/en active Active
- 2010-02-01 BR BRPI1005683-1A patent/BRPI1005683B1/pt active IP Right Grant
- 2010-02-01 MX MX2011007937A patent/MX2011007937A/es active IP Right Grant
- 2010-02-01 ES ES10702726T patent/ES2400890T3/es active Active
- 2010-02-01 ES ES16195596T patent/ES2749629T3/es active Active
- 2010-02-01 WO PCT/GB2010/000165 patent/WO2010086626A1/en not_active Ceased
- 2010-02-01 SG SG2011053014A patent/SG173102A1/en unknown
- 2010-02-01 CA CA2751130A patent/CA2751130C/en active Active
- 2010-02-01 EP EP10702726A patent/EP2391731B1/en active Active
- 2010-02-01 EP EP13152077.7A patent/EP2612925B1/en active Active
- 2010-02-01 DK DK10702726.0T patent/DK2391731T3/da active
- 2010-02-01 CN CN201080006024.8A patent/CN102301010B/zh active Active
- 2010-02-01 CN CN201510314041.2A patent/CN104911177A/zh active Pending
-
2011
- 2011-07-05 IL IL213930A patent/IL213930A/en active IP Right Grant
- 2011-07-07 ZA ZA2011/05013A patent/ZA201105013B/en unknown
-
2015
- 2015-07-30 US US14/814,258 patent/US20150329902A1/en not_active Abandoned
- 2015-09-07 JP JP2015175262A patent/JP6454243B2/ja active Active
-
2019
- 2019-02-01 US US16/265,919 patent/US11384388B2/en active Active
-
2022
- 2022-06-06 US US17/805,657 patent/US20220372565A1/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017060650A1 (fr) | 2015-10-08 | 2017-04-13 | Jean-Marc Limacher | Composition anti-tumorale |
| WO2025190971A1 (fr) | 2024-03-13 | 2025-09-18 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ594004A (en) | Production of closed linear dna | |
| IN2012DN06299A (enExample) | ||
| GB2470672A (en) | Methods of RNA aplification in the presence of DNA | |
| GB2485955B (en) | Apparatuses | |
| EP2379748A4 (en) | MULTIBASE RELEASE FOR LONG READINGS IN SEQUENCING BY SYNTHESIS PROTOCOLS | |
| WO2010002938A3 (en) | Method for direct amplification from crude nucleic acid samples | |
| WO2012145725A3 (en) | Oscillating amplification reaction for nucleic acids | |
| AU2010208386A8 (en) | Thermophilic helicase dependent amplification technology with endpoint homogenous fluorescent detection | |
| WO2016064894A3 (en) | Compositions and methods for detecting an rna virus | |
| NZ723399A (en) | Methods and compositions for dna profiling | |
| PE20110480A1 (es) | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales | |
| WO2009120374A3 (en) | Methods and compositions for nucleic acid sample preparation | |
| MX2016001157A (es) | Circularizacion y amplificacion de acidos nucleicos circulantes asistida de ligasa. | |
| MX2012002411A (es) | Metodos de ensayo para el mdv-1. | |
| ATE476528T1 (de) | Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus | |
| WO2012177695A3 (en) | Hybrid polymerases having the ability to produce long amplicons | |
| MY184132A (en) | Processes for conversion of biologically derived mevalonic acid | |
| IN2014DN03409A (enExample) | ||
| WO2012009373A3 (en) | Compositions and assays to detect swine h1n1 influenza a virus, seasonal h1 influenza a virus and seasonal h3 influenza a virus nucleic acids | |
| NZ732886A (en) | Amplification and detection of nucleic acids in a biological sample | |
| WO2012038049A3 (en) | Amplification of distant nucleic acid targets using engineered primers | |
| WO2010151566A8 (en) | Compositions and methods for detecting nucleic acid from mollicutes | |
| WO2008149855A1 (ja) | メチル化核酸又は非メチル化核酸を増幅する方法 | |
| IN2012DN00172A (enExample) | ||
| WO2014122422A3 (en) | Amplification technique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 FEB 2017 BY DENNEMEYER SA Effective date: 20140214 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2018 BY DENNEMEYER + CO Effective date: 20170120 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2019 BY DENNEMEYER + CO Effective date: 20180126 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2020 BY DENNEMEYER + CO. Effective date: 20190122 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2021 BY PETRA OLK Effective date: 20200123 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2022 BY DENNEMEYER + CO. Effective date: 20210125 |
|
| ASS | Change of ownership |
Owner name: TOUCHLIGHT IP LIMITED, GB Effective date: 20211124 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2023 BY DENNEMEYER + CO. SARL. Effective date: 20220127 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2024 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20230123 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2025 BY DENNEMEYER AND CO. SARL Effective date: 20240122 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2026 BY DENNEMEYER ET CO Effective date: 20250121 |